336191-17-4

Basic information

• Product Name: 2,8-DIAZA-SPIRO[4.5]DECANE-2-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 2,8-DIAZA-SPIRO[4.5]DECANE-2-CARBOXYLIC ACID TERT-BUTYL ESTER;TERT-BUTYL 2,8-DIAZASPIRO[4.5]DECANE-2-CARBOXYLATE;2-Boc-2,8-Diaza-spiro[4.5]decane;tert-Butyl2,7-diazaspiro[4,5]decane-2-carboxylate,98%;2-Boc-2,8-diaza-spiro[4.5...;2,8-Diazaspiro[4.5]decane, N2-BOC protected;2,8-Diaza-Spiro[4.5]Decane-2-Carboxylic acid Tert-Butyl Es;2,8-Diazaspiro[4.5]decane-2-carboxylic acid, 1,1-diMethylethyl ester
• CAS NO: 336191-17-4
• Molecular Formula: C₁₃H₂₄N₂O₂
• Molecular Weight: 240.34
• Mol File: 336191-17-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 337 °C at 760 mmHg
• Flash Point: 157.6 °C
• Appearance: /
• Density: 1.07 g/cm³
• Vapor Pressure: 0.000108mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 10.97±0.20(Predicted)
• CAS DataBase Reference: 2,8-DIAZA-SPIRO[4.5]DECANE-2-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2,8-DIAZA-SPIRO[4.5]DECANE-2-CARBOXYLIC ACID TERT-BUTYL ESTER(336191-17-4)
• EPA Substance Registry System: 2,8-DIAZA-SPIRO[4.5]DECANE-2-CARBOXYLIC ACID TERT-BUTYL ESTER(336191-17-4)

Safety Data

• Statements: 20-22-36/37/38
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 336191-17-4(Hazardous Substances Data)

Usage

Chemical Properties

Wihte powder

InChI:InChI=1/C13H24N2O2/c1-12(2,3)17-11(16)15-9-6-13(10-15)4-7-14-8-5-13/h14H,4-10H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 929301-98-4 C₂₁H₃₀N₂O₄ 
• 336191-13-0 8-benzyl-2-(4-methoxy-benzyl)-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 336191-14-1 8-benzyl-2-(4-methoxybenzyl)-2,8-diazaspiro[4.5]decane 
• 1463-52-1 ethyl 2-(1-benzylpiperidin-4-ylidene)-2-cyanoacetate 
• 34702-66-4 8-benzyl-2-oxa-8-aza-spiro[4.5]decane-1,3-dione 
• 336191-16-3 8-benzyl-2,8-diaza-spiro[4.5]decane-2-carboxylic acid tert-butyl ester 
• 86945-27-9 1-benzyl-4-cyanomethylpiperidine-4-carbonitrile 
• 40117-92-8 1-benzyl-4-carboxymethyl-piperidine-4-carboxylic acid 
• 336191-15-2 8-benzyl-2,8-diazaspiro[4.5]decane 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 742067-24-9 8-acetyl-2,8-diaza-spiro[4.5]decane-2-carboxylic acid tert-butyl ester 
• 742067-22-7 8-methane sulfonyl-2,8-diaza-spiro[4.5]decane-2-carboxylic acid tert-butyl ester 
• 1246508-26-8 tert-butyl 8-(4-cyanophenyl)-2,8-diazaspiro[4.5]decane-2-carboxylate 
• 1246508-27-9 tert-butyl 8-(4-methoxyphenyl)-2,8-diazaspiro[4.5]decane-2-carboxylate 
• 1246508-17-7 tert-butyl 8-(5-(trifluoromethyl)pyrimidin-2-yl)-2,8-diazaspiro[4.5]decane-2-carboxylate 
• 1570262-37-1 tert-butyl 8-[2-(biphenyl-3-ylamino)-5-cyanopyrimidin-4-yl]-2,8-diazaspiro[4.5]decane-2-carboxylate 
• 1570258-91-1 2-(biphenyl-3-ylamino)-4-(2,8-diazaspiro[4.5]dec-8-yl)pyrimidine-5-carbonitrile 
• 959640-90-5 8-cyclobutyl-2,8-diaza-spiro[4.5]decane 
• 1312573-03-7 tert-butyl 8-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]-2,8-diazaspiro[4.5]decane-2-carboxylate 
• 1372534-58-1 tert-butyl 8-(2-chlorofuro[3,2-d]pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-2-carboxylate 
• 1354947-84-4 1,1-dimethylethyl 8-({1-[4-cyano-3-(trifluoromethyl)phenyl]-1H-tetrazol-5-yl}methyl)-2,8-diazaspiro[4.5]decane-2-carboxylate 
• 1258000-10-0 C₂₆H₃₂F₂N₂O₂ 
• 1246507-93-6 tert-butyl 8-(4-(trifluoromethyl)phenyl)-2,8-diazaspiro[4.5]decane-2-carboxylate 

Relevant articles and documents

SUBSTITUTED AZASPIRO DERIVATIVES

Substituted azaspiro derivatives of the Formula:are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS

Spirocyclic sulfonamides and related compounds of Formula 1 are provided : (Formula (I)): in which the variables are as described herein. Such compounds may be used to modulate bradykinin receptor activity in vivo or in vitro, and are particularly useful

Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation

Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis